查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1573069

阻塞性支氣管炎症候群市場：依疾病類型、治療類型、最終用戶、藥物類型、給藥途徑、患者特徵、診斷方法 - 2025-2030 年全球預測

Bronchiolitis Obliterans Syndrome Market by Disease Type, Treatment Type, End-User, Drug Type, Route of Administration, Patient Demographics, Diagnosis Method - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年阻塞性支氣管炎症候群市值為6,753萬美元，預估至2024年將達7,325萬美元，複合年成長率為8.37%，至2030年將達1,1854萬美元。

閉塞性支氣管炎症候群 (BOS) 是一種嚴重的進行性性肺部疾病，通常與肺移植患者的慢性排斥反應有關，導致小氣道閉塞。除了支持性護理和免疫抑制劑之外，管理方法的進展有限，凸顯了對 BOS 進行針對性研究和治療應用的必要性。因此，醫院、研究機構和移植中心在最終用途上佔據顯著地位，凸顯了對專門治療方法和診斷工具的需求。根據市場洞察，肺移植數量的增加和對移植後併發症認知的提高是關鍵的成長要素。診斷方法的技術進步，例如成像技術和生物標記，正在為相關人員創新和利用新技術創造潛在機會。抓住這些機會的建議包括投資下一代治療和診斷方法的研究和開發，以提供早期檢測和個人化治療策略。然而，市場成長受到臨床試驗的複雜性和成本、監管障礙以及缺乏有效治療方法等挑戰的阻礙。為了應對這些挑戰，生技公司、研究機構和監管機構必須共同努力，簡化流程並加速新治療方法的發現。最具創新潛力的領域包括開發非侵入性診斷工具、精準醫學方法和肺組織修復的再生療法。 BOS 市場的高度專業化和研究主導的性質要求關注臨床醫生和行業研究人員之間的長期夥伴關係和知識交流。此外，將人工智慧整合到臨床決策、患者結果的預測分析以及用於遠端監測 BOS 患者的遠端醫療平台將有助於克服地理障礙並最佳化這一利基市場的資源分配，並有可能進一步增加研究。

主要市場統計
基準年[2023] 6753萬美元
預測年份 [2024] 7325萬美元
預測年份 [2030] 11854萬美元
複合年成長率（%） 8.37%

市場動態：快速發展的支氣管炎阻塞性綜合症市場的關鍵市場洞察

阻塞性支氣管炎綜合症市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 醫療技術和治療的進步可以更好地治療阻塞性支氣管炎症候群
    • 肺部疾病盛行率的增加導致對阻塞性支氣管炎症候群治療的需求增加
    • 增加醫療支出和政府資助以支持阻塞性細支氣管炎的研究和開發
    • 提高醫療保健專業人員和患者對阻塞性支氣管炎症候群及其治療方法的認知
  • 市場限制因素
    • 阻塞性支氣管炎症候群的研究經費和投資有限正在阻礙進展。
  • 市場機會
    • 治療阻塞性支氣管炎症候群患者的先進治療方法的出現
    • 擴大阻塞性支氣管炎症候群創新治療方法的研發活動
    • 擴大宣傳宣傳活動以促進阻塞性支氣管炎症候群的早期發現
  • 市場挑戰
    • 嚴格的監管核准流程減緩了阻塞性支氣管炎症候群的新治療方法

波特的五力：駕馭阻塞性支氣管炎症候群市場的策略工具

波特的五力架構是了解阻塞性支氣管炎症候群市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解支氣管炎阻塞性綜合症市場的外部影響

外部宏觀環境因素在塑造支氣管炎阻塞性綜合症市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解阻塞性支氣管炎症候群市場的競爭狀況

阻塞性支氣管炎綜合症市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣阻塞性支氣管炎症候群市場供應商的績效評估

FPNV 定位矩陣是評估阻塞性支氣管炎症候群市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了阻塞性支氣管炎綜合症市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對阻塞性支氣管炎綜合症市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 醫療技術和治療方法的進步改善了阻塞性支氣管炎綜合症的治療
      • 肺部疾病盛行率的增加導致對阻塞性支氣管炎症候群治療方法的需求增加
      • 不斷上漲的醫療成本和政府資助推動阻塞性細支氣管炎的研究和開發
      • 醫療保健專業人員和患者對阻塞性支氣管炎症候群及其治療方法的認知不斷提高
    • 抑制因素
      • 阻塞性支氣管炎症候群的研究經費和投資有限阻礙了進展
    • 機會
      • 治療阻塞性支氣管炎症候群患者的新先進治療方法
      • 擴大阻塞性支氣管炎症候群創新治療方法的研發活動
      • 擴大宣傳宣傳活動，加強阻塞性支氣管炎症候群的早期發現
    • 任務
      • 嚴格的監管核准程序減緩了阻塞性支氣管炎症候群的新治療方法
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 阻塞性支氣管炎症候群市場：依疾病類型

  • 阻塞性支氣管炎症候群
  • 阻塞性細支氣管炎綜合症

第7章阻塞性支氣管炎症候群市場：依治療類型

  • 非藥物治療
    • 氧氣療法
    • 呼吸復健
    • 手術治療
  • 藥物治療
    • 抗生素
    • 皮質類固醇
    • 免疫抑制劑

第8章阻塞性支氣管炎症候群市場：依最終用戶

  • 門診手術中心
  • 家庭護理設置
  • 醫院
  • 專科診所

第9章阻塞性支氣管炎症候群市場：依藥物類型

  • 品牌
  • 非專利的

第 10 章 阻塞性支氣管炎症候群市場：依給藥途徑

  • 吸入
  • 靜脈
  • 口服

第11章阻塞性支氣管炎症候群市場：依病患屬性

  • 成人用
  • 老年病
  • 小兒科

第12章阻塞性支氣管炎症候群市場：依診斷方法

  • 驗血
  • 高解析度電腦斷層掃描
  • 切片檢查
  • 肺功能檢查

第13章美洲阻塞性支氣管炎症候群市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第14章亞太地區阻塞性支氣管炎症候群市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第15章歐洲/中東/非洲阻塞性支氣管炎症候群市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca
  • 4. Boehringer Ingelheim
  • 5. Bristol-Myers Squibb Company
  • 6. Chiesi Farmaceutici SpA
  • 7. Eli Lilly and Company
  • 8. FibroGen, Inc.
  • 9. Gilead Sciences
  • 10. GlaxoSmithKline plc
  • 11. Insmed Incorporated
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Roche Holding AG
  • 16. Sanofi
  • 17. Sunovion Pharmaceuticals Inc.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. Theravance Biopharma
Product Code: MRR-535C62918A91

The Bronchiolitis Obliterans Syndrome Market was valued at USD 67.53 million in 2023, expected to reach USD 73.25 million in 2024, and is projected to grow at a CAGR of 8.37%, to USD 118.54 million by 2030.

Bronchiolitis Obliterans Syndrome (BOS) is a severe, progressive lung condition often associated with chronic rejection in lung transplant patients, leading to obliteration of the small airways. The necessity for targeted research and treatment applications of BOS is underscored by the limited advancements in management approaches beyond supportive care and immunosuppressive drugs. Consequently, the end-use scope prominently features hospitals, research institutions, and transplantation centers, emphasizing the need for specialized therapies and diagnostic tools. Market insights reveal that the rising number of lung transplants and increased awareness of post-transplant complications are significant growth factors. Technological advancements in diagnostic methodologies, such as imaging techniques and biomarkers, are creating potential opportunities for stakeholders to innovate and capitalize on emerging technologies. Recommendations to seize these opportunities include investing in R&D for next-generation therapeutics and diagnostics that can provide early detection and personalized treatment strategies. However, market growth is challenged by limitations such as the complexity and cost of clinical trials, regulatory hurdles, and the scarcity of effective therapeutic options. Addressing these challenges requires collaborative efforts between biotechnology firms, research institutes, and regulatory bodies to streamline processes and encourage novel therapeutic discoveries. Areas offering the best potential for innovation include the development of non-invasive diagnostic tools, precision medicine approaches, and regenerative therapies aimed at lung tissue repair. The nature of the BOS market is highly specialized and research-driven, necessitating a focus on long-term partnerships and knowledge exchange between clinicians and industry researchers. Moreover, the integration of artificial intelligence in clinical decision-making, predictive analytics for patient outcomes, and telemedicine platforms for remote monitoring of BOS patients could further augment research and business growth, overcoming geographical barriers and optimizing resource allocation within this niche market.

KEY MARKET STATISTICS
Base Year [2023] USD 67.53 million
Estimated Year [2024] USD 73.25 million
Forecast Year [2030] USD 118.54 million
CAGR (%) 8.37%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bronchiolitis Obliterans Syndrome Market

The Bronchiolitis Obliterans Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Advancements in medical technology and treatments leading to better management of bronchiolitis obliterans syndrome
    • Increasing prevalence of lung diseases contributing to higher demand for bronchiolitis obliterans syndrome therapies
    • Rising healthcare expenditure and government funding boosting research and development in bronchiolitis obliterans
    • Growing awareness among healthcare professionals and patients about bronchiolitis obliterans syndrome and its treatments
  • Market Restraints
    • Limited research funding and investment in bronchiolitis obliterans syndrome hindering advancements
  • Market Opportunities
    • Emerging advanced therapeutic approaches to treat bronchiolitis obliterans syndrome patients
    • Growing research and development activities for innovative bronchiolitis obliterans syndrome treatments
    • Expanding public awareness campaigns to enhance early detection of bronchiolitis obliterans syndrome
  • Market Challenges
    • Stringent regulatory approval processes delaying new treatments for bronchiolitis obliterans syndrome

Porter's Five Forces: A Strategic Tool for Navigating the Bronchiolitis Obliterans Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bronchiolitis Obliterans Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bronchiolitis Obliterans Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bronchiolitis Obliterans Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bronchiolitis Obliterans Syndrome Market

A detailed market share analysis in the Bronchiolitis Obliterans Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bronchiolitis Obliterans Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bronchiolitis Obliterans Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bronchiolitis Obliterans Syndrome Market

A strategic analysis of the Bronchiolitis Obliterans Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchiolitis Obliterans Syndrome Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Chiesi Farmaceutici S.p.A., Eli Lilly and Company, FibroGen, Inc., Gilead Sciences, GlaxoSmithKline plc, Insmed Incorporated, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Theravance Biopharma.

Market Segmentation & Coverage

This research report categorizes the Bronchiolitis Obliterans Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Bronchiolitis Obliterans Syndrome and Non-Bronchiolitis Obliterans Syndrome.
  • Based on Treatment Type, market is studied across Non-Pharmacological Treatment and Pharmacological Treatment. The Non-Pharmacological Treatment is further studied across Oxygen Therapy, Pulmonary Rehabilitation, and Surgical Therapy. The Pharmacological Treatment is further studied across Antibiotics, Corticosteroids, and Immunosuppressive Agents.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Homecare Settings, Hospitals, and Specialty Clinics.
  • Based on Drug Type, market is studied across Branded and Generic.
  • Based on Route of Administration, market is studied across Inhalation, Intravenous, and Oral.
  • Based on Patient Demographics, market is studied across Adult, Geriatric, and Pediatric.
  • Based on Diagnosis Method, market is studied across Blood Tests, High-Resolution CT Scan, Lung Biopsy, and Pulmonary Function Tests.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Advancements in medical technology and treatments leading to better management of bronchiolitis obliterans syndrome
      • 5.1.1.2. Increasing prevalence of lung diseases contributing to higher demand for bronchiolitis obliterans syndrome therapies
      • 5.1.1.3. Rising healthcare expenditure and government funding boosting research and development in bronchiolitis obliterans
      • 5.1.1.4. Growing awareness among healthcare professionals and patients about bronchiolitis obliterans syndrome and its treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Limited research funding and investment in bronchiolitis obliterans syndrome hindering advancements
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging advanced therapeutic approaches to treat bronchiolitis obliterans syndrome patients
      • 5.1.3.2. Growing research and development activities for innovative bronchiolitis obliterans syndrome treatments
      • 5.1.3.3. Expanding public awareness campaigns to enhance early detection of bronchiolitis obliterans syndrome
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory approval processes delaying new treatments for bronchiolitis obliterans syndrome
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bronchiolitis Obliterans Syndrome Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Bronchiolitis Obliterans Syndrome
  • 6.3. Non-Bronchiolitis Obliterans Syndrome

7. Bronchiolitis Obliterans Syndrome Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Non-Pharmacological Treatment
    • 7.2.1. Oxygen Therapy
    • 7.2.2. Pulmonary Rehabilitation
    • 7.2.3. Surgical Therapy
  • 7.3. Pharmacological Treatment
    • 7.3.1. Antibiotics
    • 7.3.2. Corticosteroids
    • 7.3.3. Immunosuppressive Agents

8. Bronchiolitis Obliterans Syndrome Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Homecare Settings
  • 8.4. Hospitals
  • 8.5. Specialty Clinics

9. Bronchiolitis Obliterans Syndrome Market, by Drug Type

  • 9.1. Introduction
  • 9.2. Branded
  • 9.3. Generic

10. Bronchiolitis Obliterans Syndrome Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Inhalation
  • 10.3. Intravenous
  • 10.4. Oral

11. Bronchiolitis Obliterans Syndrome Market, by Patient Demographics

  • 11.1. Introduction
  • 11.2. Adult
  • 11.3. Geriatric
  • 11.4. Pediatric

12. Bronchiolitis Obliterans Syndrome Market, by Diagnosis Method

  • 12.1. Introduction
  • 12.2. Blood Tests
  • 12.3. High-Resolution CT Scan
  • 12.4. Lung Biopsy
  • 12.5. Pulmonary Function Tests

13. Americas Bronchiolitis Obliterans Syndrome Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Bronchiolitis Obliterans Syndrome Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Bronchiolitis Obliterans Syndrome Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca
  • 4. Boehringer Ingelheim
  • 5. Bristol-Myers Squibb Company
  • 6. Chiesi Farmaceutici S.p.A.
  • 7. Eli Lilly and Company
  • 8. FibroGen, Inc.
  • 9. Gilead Sciences
  • 10. GlaxoSmithKline plc
  • 11. Insmed Incorporated
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Roche Holding AG
  • 16. Sanofi
  • 17. Sunovion Pharmaceuticals Inc.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. Theravance Biopharma

LIST OF FIGURES

  • FIGURE 1. BRONCHIOLITIS OBLITERANS SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. BRONCHIOLITIS OBLITERANS SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. BRONCHIOLITIS OBLITERANS SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRONCHIOLITIS OBLITERANS SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRONCHIOLITIS OBLITERANS SYNDROME MARKET DYNAMICS
  • TABLE 7. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BRONCHIOLITIS OBLITERANS SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-BRONCHIOLITIS OBLITERANS SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PULMONARY REHABILITATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SURGICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSIVE AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HIGH-RESOLUTION CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY LUNG BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 206. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 215. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 234. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 243. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 252. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 261. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 270. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 279. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 287. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 288. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SI